Δεκ272013Βιβλιογραφικά δεδομέναIncidence of Colorectal Cancer After Liver Transplantation for Primary Sclerosing Cholangitis: A Systematic Review and Meta-Analysis Κατηγορία Βιβλιογραφικά δεδομένα27 Δεκεμβρίου 2013 Μοιραστείτε το! Share on FacebookShare on Facebook Share on XShare on X Share on LinkedInShare on LinkedIn Share on WhatsAppShare on WhatsApp Post navigationΠροηγούμενοPrevious post:Conversion From Prograf to Advagraf in Adolescents With Stable Liver Transplants: Comparative Pharmacokinetics and 1-Year Follow-UpΕπόμενοNext post:Off-Therapy Durability of Response to Entecavir Therapy in Hepatitis B e Antigen-Negative Chronic Hepatitis B PatientsΣχετικά ΆρθραThe burden of extrahepatic organ failures in European patients with cirrhosis15 Δεκεμβρίου 2025Linerixibat in patients with primary biliary cholangitisand cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial28 Νοεμβρίου 2025Sex and body size disparities under MELD 3.0: Evaluation of persisting gaps in liver transplant access16 Νοεμβρίου 2025Prognostic implications of recompensation of decompensated cirrhosis after SVR in patients with hepatitis C6 Νοεμβρίου 2025Meta- Analysis: Comparison of Living Versus Deceased Liver Transplantation for Primary Sclerosing Cholangitis4 Νοεμβρίου 2025Development and validation of a risk prediction model for patients with hepatocellular carcinoma receiving atezolizumab-bevacizumab27 Οκτωβρίου 2025
Linerixibat in patients with primary biliary cholangitisand cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial28 Νοεμβρίου 2025
Sex and body size disparities under MELD 3.0: Evaluation of persisting gaps in liver transplant access16 Νοεμβρίου 2025
Prognostic implications of recompensation of decompensated cirrhosis after SVR in patients with hepatitis C6 Νοεμβρίου 2025
Meta- Analysis: Comparison of Living Versus Deceased Liver Transplantation for Primary Sclerosing Cholangitis4 Νοεμβρίου 2025
Development and validation of a risk prediction model for patients with hepatocellular carcinoma receiving atezolizumab-bevacizumab27 Οκτωβρίου 2025
